LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd (“Engitix”), a biotech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today ...
LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human ...
UK-based biotechnology company Engitix Ltd. has raised a further $25 million from billionaire Michael Platt to help develop its therapies for cancer and fibrosis.
(MENAFN- GlobeNewsWire - Nasdaq) Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback